Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study. - Wikidata - awgldk - TriplyDB

Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study.

Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study.

http://www.wikidata.org/entity/Q34293797

about

Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.A model of hematopoietic stem cell proliferation under the influence of a chemotherapeutic agent in combination with a hematopoietic inducing agent.

P2860

Q38226486-2FC3184B-5F77-4E94-A305-DC38EE098BB1 Q41887008-04C097B7-C7AF-4D84-A02A-2FBCA03543E5

P2860

Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study.

http://www.wikidata.org/entity/Q34293797

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Incidence of febrile neutropen ...... t cancer: a prospective study.

@ast

Incidence of febrile neutropen ...... t cancer: a prospective study.

@en

Incidence of febrile neutropen ...... t cancer: a prospective study.

@nl

type

label

Incidence of febrile neutropen ...... t cancer: a prospective study.

@ast

Incidence of febrile neutropen ...... t cancer: a prospective study.

@en

Incidence of febrile neutropen ...... t cancer: a prospective study.

@nl

prefLabel

Incidence of febrile neutropen ...... t cancer: a prospective study.

@ast

Incidence of febrile neutropen ...... t cancer: a prospective study.

@en

Incidence of febrile neutropen ...... t cancer: a prospective study.

@nl

P1433

Q34293797-3D0E97D8-05A5-4C64-8A8B-8532CE34B8C3

P1476

Q34293797-26E0ABC6-B432-4EEC-B2BD-3D5F0569F11D

P2093

Q34293797-0C660D0C-3A8D-4E2D-BD8D-8C41B7EF3DAF

Q34293797-4267EFB0-66E1-47FE-AECB-F9D6A05BBCF5

Q34293797-51FE29C3-0F93-4B80-BD5E-D32FEDD5AFFD

Q34293797-609F84BB-6C6E-4D50-A29E-32A5C7BD962C

Q34293797-66602317-5D02-4237-9226-09164E5FEA68

Q34293797-7B7B1BBF-1C84-4863-B53B-69AC875D7DA2

Q34293797-A5202509-7B8E-48F3-8730-895D1339E385

Q34293797-B1B79EE4-4D78-491A-9AB3-4AD4F2F710C3

Q34293797-E5E1A4D9-E27B-42BD-BE39-C8B390E7F7E1

P2860

Q34293797-457F2A1A-ED40-4204-8D68-1374D50683A3

Q34293797-47C23013-D7B0-41F9-AFE1-5867619B1A92

Q34293797-565BB78F-4FBA-4700-A359-A9B80F53BDFA

Q34293797-75EA79E2-B794-4218-9399-30AD40061EA0

Q34293797-9CF625B5-A314-44E0-9007-54B2137A609E

Q34293797-C7BD4281-6C86-4084-B8E6-3DDD7CD8E759

Q34293797-E33FC0D4-9AD2-4027-AD8C-82DE52DD367F

P304

Q34293797-FE77CD06-2CB2-424B-BABF-C23FBE1A7DE4

P31

Q34293797-34BC0843-8720-41BD-9C1E-D2DD1708D959

P356

Q34293797-FCBA1E39-55D7-41B5-807E-6AB822C0E89B

P433

Q34293797-BD8439C0-EDDF-4C58-BD1B-AA4AD92CEB0E

P478

Q34293797-94D43796-33B1-413C-84A7-0204EE12D7A2

P577

Q34293797-2DFE60C2-5C99-4370-8EEB-88D9FAFF93FE

P5875

Q34293797-5EC696E2-94FC-4634-BF6E-8A7E1402D178

P698

Q34293797-EB53A662-2E25-43C1-834F-40D36AA11E61

P921

Q34293797-84FF4196-FFA0-4DE2-856B-D7C49910421B

P932

Q34293797-CF83A22B-5503-43C6-B61F-4EF224E7A590

P356

P1433

Current Oncology

P1476

Incidence of febrile neutropen ...... t cancer: a prospective study.

@en

P2093

A Drucker

http://www.w3.org/2001/XMLSchema#string

A Jeyakumar

http://www.w3.org/2001/XMLSchema#string

B Colwell

http://www.w3.org/2001/XMLSchema#string

D Rayson

http://www.w3.org/2001/XMLSchema#string

M Dorreen

http://www.w3.org/2001/XMLSchema#string

M Sellon

http://www.w3.org/2001/XMLSchema#string

S Lutes

http://www.w3.org/2001/XMLSchema#string

S Snow

http://www.w3.org/2001/XMLSchema#string

T Younis

http://www.w3.org/2001/XMLSchema#string

P2860

A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer

Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres

Hematopoietic growth factors: ESMO recommendations for the application.

High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide.

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

P304

e216-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.19.940

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225273511

http://www.w3.org/2001/XMLSchema#string

P698

22670112

http://www.w3.org/2001/XMLSchema#string

P921

P932

3364783

http://www.w3.org/2001/XMLSchema#string